Home / Transcripts / Arvinas, Inc. (ARVN) · August 4, 2026

Arvinas, Inc. (ARVN) Earnings Call Transcript

August 4, 2026

NASDAQ US Health Care Pharmaceuticals earnings 48 min

Earnings Call Speaker Segments

Jeff Boyle executive
#1

Hello, everybody, and thanks for being with us. We put out a press release earlier today covering the financial results for our second quarter of 2026, and you can find it in the Investor and Media section on our site, arvinas.com. On the line with us now are Randy Teel, who serves as our President and Chief Executive Officer; Angela Cacace, our Chief Scientific Officer; and our Chief Financial Officer, Andrew Saik. I want to note before we get started that forward-looking statements are part of what we'll be discussing today, and those come with risks, uncertainties and assumptions. You'll find these risks and uncertainties described in the press release issued today as well as in the company's recent filings with the Securities and Exchange Commission, and I encourage you to review them. What actually happens could end up differing materially from what we talk about on this call. A replay of today's call, along with the press release and a refreshed corporate deck, will be posted in the Investor and Media section of our website. At this point, I'll hand things over to Randy Teel. Randy?

Randy Teel executive
#2

Appreciate that, Jeff, and good morning to all of you. Over the last several months, this company has achieved meaningful progress. We've concentrated on getting Arvinas ready for the coming stage of expansion, steering by a well-defined strategic roadmap. At the heart of that roadmap sits an unwavering commitment to pushing forward transformative gains for patients. By sustaining innovation and executing with discipline, our aim is to release the complete promise of our pipeline for patients as well as shareholders. Since the year began, we've hit 3 notable strategic milestones. The first was the inaugural FDA approval ever granted to a PROTAC degrader, VEPPANU. Next, we completed an out-licensing arrangement for VEPPANU with Rigel Pharmaceuticals, and they anticipate getting that therapy to patients very soon. Then there's the third item: we made a strategic decision that ARV-806, which is our KRAS G12D program, will move forward solely with a partner. We do believe 806 has the potential to be a meaningful option for treating patients, but pursuing it would require a level of spending that doesn't fit with the way we're allocating capital right now. When you look at all of this together, everything we achieved and chose during the first half of 2026 has positioned Arvinas to fully capture the promise of our platform in both oncology and neurology. All of our focus is now on the Phase I clinical programs, and we have strong confidence in the chance ahead of us to develop meaningful treatments for patients. That said, I want to spend a few minutes providing more detail on our three assets that have major clinical data catalysts coming up over the next 12 months. I'll go through what sets each of them apart, as well as the strong value each offers. Starting with ARV-393, our BCL6 degrader, I'll explain what makes BCL6 a compelling target, describe where the trial currently stands, and share what you should expect when we release data later in 2026. BCL6 is an exciting therapeutic target that has initial clinical validation. BCL6, a transcription factor that had no prior drugs targeting it, acts as a key controller governing several cellular functions throughout B-cell development, including proliferation, survival, and apoptosis. In multiple non-Hodgkin lymphoma subtypes, changes in BCL6 activity have been identified as a driving force behind cancer growth. We think ARV-393 has the potential to serve as a cornerstone therapy and to lead the way as the initial completely oral, chemotherapy-free strategy for individuals with B or T-cell lymphomas. When our BCL6 program first began, not a single company had managed to show successful degradation of BCL6 or advance any degrader into clinical testing. Based on what the FDA told us, we began the trial at dose levels that were considerably lower than the exposure we had projected would be efficacious. That decision created problems with getting patients enrolled and stretched out the enrollment timeline. Even with that, enrollment has clearly picked up speed now that we're dosing nearer to the range where we expect efficacy. At the same time, the glofi combo arm of the study has drawn strong enrollment since it launched a few months ago. And as we shared late last year, even at dose levels we wouldn't have anticipated being efficacious, we've seen early responses in hard-to-treat T-cell lymphomas such as AITL, and also in B-cell lymphoma patients. Regarding the forthcoming data for ARV-393, we remain on schedule to report initial Phase I results before this year concludes. Continued dose escalation has been possible thanks to our safety profile, even though most of the 2026 data will come from the early cohorts that were dosed beneath the expected efficacious range. Those early cohorts, relative to the overall lymphoma population, contain a greater-than-anticipated share of patients with T-cell lymphomas, which probably mirrors the scarce treatment choices available to them. Yet, as I noted, once we drew near the predicted efficacious range, patient enrollment grew, among them individuals with B-cell lymphomas; during 2027, we intend to make a later disclosure containing more mature monotherapy data, covering patients with DLBCL who received ARV-393, given both as monotherapy and alongside glofi. We hold strong optimism regarding this program's potential to help patients whose clinical outcomes have historically been poor, particularly in light of the encouraging feedback investigators have given us across the last few months. Now I'll shift to ARV-027, our degrader aimed at polyglutamine repeat androgen receptor, or polyQ-AR. The first thing that jumps out regarding this program is the fact that polyQ-AR protein is broadly acknowledged as the underlying cause of pathology in people who suffer from spinal and bulbar muscular atrophy, or SBMA — a condition that also goes by the name Kennedy's disease. SBMA belongs to the category of rare neuromuscular disorders, and it impacts somewhere in the range of 10,000 to 13,000 patients who have received a diagnosis throughout major markets. According to genomic research, SBMA remains significantly underdiagnosed, and ARV-027 has the potential to be the first therapy able to go after the disease's main driver. An X-linked disease, SBMA results from toxic accumulation of the polyQ-AR protein inside skeletal muscle. Such buildup disrupts normal muscle function, drives muscular atrophy and, as time passes, leaves patients dealing with long-term physical disabilities and often incapable of completing daily activities. Since ARV-027 is taken by mouth, it could hold a distinct advantage as a handy option for breaking down the protein responsible for this condition. Back in February, we presented preclinical findings that support what ARV-027 may be able to do in SBMA. Drawing on preclinical evidence already published, we'd established a goal of achieving polyQ-AR degradation in skeletal muscle above 50%, since we believed that threshold would translate into functional improvement. When tested in an aggressive mouse model of SBMA, 027 delivered substantial improvements in grip strength, endurance and survival. Notably, while we don't believe PolyQ needs to be wiped out entirely for patients to benefit therapeutically, our preclinical work did demonstrate that 027 was capable of driving AR degradation far past the amounts required for functional gains. I've got some good news from our current Phase I study in healthy volunteers: we've completed the single ascending dose groups, and we've moved into the multiple dose stage. ARV-027 is the first degrader we've aimed at a muscle target. So for this Phase I trial, there are two things we need to demonstrate that we've never demonstrated before in human muscle tissue. Getting sufficient exposure is the initial objective, and the second one is showing AR degradation within muscle. Taken together, the results from healthy volunteers should give us proof of mechanism for ARV-027 and remove a significant level of risk from the program. During the opening six months of next year, we plan to present data on both of those measures, along with the first safety findings from the trial. Once dosing in healthy volunteers is done, the next step we have in mind is giving the drug to patients who have SBMA. A multiple dose cohort in SBMA patients is already part of the Phase I design. Our view is that this approach will speed up our development plan, with the possibility of advancing to a registrational study once the Phase I trial wraps up. Last, I'll turn to ARV-102, the third of our programs with clinical data coming, and talk about our plans for upcoming disclosures, plus give a quick update on how our regulatory interactions are going as we get the next trials ready for our LRRK2 degrader. As a reminder, no approved disease-modifying treatments exist for patients with PSP or PD, and we think 102 could become a paradigm-shifting therapy for them. Biomarker data we presented in March at AD/PD back this up. Those findings were the first to demonstrate modulation of key biomarkers involved in PSP as well as PD, something LRRK2 inhibitors have not achieved. That strengthens the case for 102 as a unique approach in neurodegenerative diseases. At the MDS conference in October, we'll share further biomarker data from the Phase I trial, among it ocular motor measures and CSF proteomics. Regarding our regulatory interactions for 102, as you'll remember, we're right now working to get clinical trials started for 102 in PSP patients, in the U.S; and around the world. Having successfully finished our Phase I trial in the Netherlands earlier this year, we filed an IND with the FDA to back the launch of the Phase Ib trial in the first half of the year. As we said before, before giving the go-ahead to start the trial, the FDA asked for extra information and final data from our chronic tox studies, and those are now complete. Over the quarter, we've also engaged productively with health authorities in both Europe and Japan. Talks with the agencies continue, and we look forward to bringing you an update on when we'll begin our next clinical trials, which we now expect to start in 2027. Zooming out, what we achieved and the decisive steps we took in the first half of 2026 show we can embrace change, seize new opportunities and execute efficiently. Every person across Arvinas has my admiration for the way we've directed our resources decisively toward the chances that hold the most promise for the company. Through careful stewardship of our capital, we're giving precedence to initiatives aimed at serious unmet medical needs that also offer considerable commercial upside. The way our pipeline is structured lets us pursue the greatest possible clinical benefit while also serving shareholder value over the long run; having said that, I'll turn things over to Angela. Angela?

Angela Cacace executive
#3

Thanks, Randy. At Arvinas, our strategy for creating breakthrough medicines starts by picking the right biology. The key choice involves finding targets where targeted protein degradation has the power to truly alter how a disease progresses. We began with two targets that were already well validated, the androgen receptor and the estrogen receptor, to prove what our degrader platform could do in the clinic. Now we're using those very same ideas to create a next wave of differentiated, disease-modifying drugs spanning oncology and neurology. Randy already walked through how our clinical portfolio is advancing, so I want to take a few minutes to focus on two oncology research programs that show where we think protein degradation offers advantages nothing else can. Let me start with ARV-6723, an oral degrader of HPK1 and the first PROTAC we've taken into immuno-oncology. Think of HPK1 as a built-in brake on the immune system. It curbs T cell activation and holds back antitumor immunity. The tricky part is that HPK1's biology goes past what its kinase activity does. HPK1 additionally serves as a signaling scaffold. Because of that, drugs that block only the kinase activity still leave some of the biology untouched. Degradation, by contrast, wipes out both the kinase and the scaffolding functions, and we think that explains why ARV-6723 has shown a preclinical profile that sets it apart from inhibitors. In many different tumor models, including ones with high immunogenicity and ones with low, ARV-6723 delivered strong antitumor activity. In those studies, degradation beat an HPK1 inhibitor as well as anti-PD-1 therapy used by itself, every time. What may be most thrilling is what we saw in tumors resistant to checkpoint therapy. Across seven preclinical models, ARV-6723 showed meaningful activity as a single agent in cases where an HPK1 inhibitor and anti-PD-1 therapy each failed to provide any benefit. We further showed preclinically that this biology reaches far past T cell activation. Degrading HPK1 could reshape the tumor microenvironment by boosting interferon signaling and activating the myeloid compartment. We suspect this wider immune remodeling stems from removing the scaffolding activity, which is what drives the differentiated profile we've seen, and should that carry over into patients, it might enable broader combination approaches and activity in tumors that historically have not responded well to immunotherapy. We're eager to start bringing these findings into the clinic. Enrollment for our Phase I study should still begin within the next few weeks, and we're looking forward to providing updates as this program moves ahead. Last, I want to call attention to our oral pan-KRAS degrader program, a first-in-class effort. We shared preclinical data not long ago showing it could potentially get past the main shortcomings of today's pan-RAS inhibitors. Our lead oral degrader demonstrated powerful activity across a wide range of KRAS mutations. Notably, this lead oral pan-KRAS degrader goes after KRAS mutations present in over 90% of patients whose cancers carry KRAS alterations, among them mutations that are hard to treat, like G12R and Q61. It further showed activity against KRAS amplification, which is a key resistance mechanism. On top of that, we saw better antitumor activity when combining it with immune checkpoint blockade, which points to the possibility of favorably reshaping the tumor microenvironment in a manner inhibitors cannot. Taken together, these results back the potential for broad activity in cancers driven by KRAS, a differentiated therapeutic index, and wide-ranging combination opportunities. We'll be presenting these exciting combination data at a scientific conference coming up soon. The team keeps delivering excellent results, and we can't wait to bring you more news in the months ahead; so with that, I'll hand things over to Andrew, who will walk us through the financial results for the quarter. Andrew?

Andrew Saik executive
#4

Appreciate that, Angela, and hello everybody on this morning's call. It's my pleasure to walk through the financial highlights for Q2 2026. Just to remind you, the full details of our second quarter financial results can be found in the press release that went out earlier today. Echoing what the team has said, there's a great deal ahead of us in the remainder of this year, and we feel good about the strong financial footing we have, which supports our ability to keep moving our pipeline forward through the second half of 2028. At the close of Q2, our balance sheet showed $567.9 million in cash, cash equivalents and marketable securities, versus $685.4 million as of the end of 2025. Given our solid balance sheet and our emphasis on the early pipeline, we're in a good position to keep developing our promising oncology and neurology programs. The second quarter was quite busy for us, since during that period we obtained FDA approval for VEPPANU, the first PROTAC degrader ever approved, along with regulatory approval for the Rigel license agreement; both of these events had a major effect on our financial statements, and I'll summarize that for you now. To start, because of the license agreement with Rigel, we booked license revenue of $62.5 million, and $35 million of that came in during the quarter. We also determined that the approach we had been using to recognize revenue under the original Pfizer agreement can no longer be applied under ASC 606, given the Rigel agreement. So we shifted all deferred revenue into the P&L, producing net revenue of $126.4 million, and we set up a liability of $52.7 million to cover what we still owe on completing ongoing development activities. On top of that, we recorded a $50 million milestone from Pfizer that was triggered by the VEPPANU approval. And separately, we recorded $3.5 million in revenue from a Pfizer research collaboration agreement for which the research term has wrapped up. Total revenue for the quarter came to $249.7 million. Now on to expenses. During the quarter, we added a new line called cost of license revenue, which covers royalties and other amounts owed to third parties that are directly tied to revenue from our licensing agreements. Cost of license revenue for Q2 was $9 million. That $9 million consists of payments to Yale under the amended Yale agreement, triggered by the FDA's approval of VEPPANU and by entering into the Rigel license agreement. General and administrative expenses came to $24 million in the second quarter, versus $25.3 million in the same period of 2025. That $1.3 million decrease was mainly driven by reductions in personnel and infrastructure-related costs of $3.9 million and costs tied to developing our commercial operations of $1.4 million, partly offset by a $4.2 million rise in professional fees, largely due to the Rigel license agreement. Research and development expenses were $52.6 million in Q2, compared to $68.6 million in the same period of 2025. That $16 million drop came mostly from an $11 million reduction in compensation and related personnel expenses, which aren't allocated by program, along with a $0.6 million decrease in program-specific expenses and a $2.6 million decrease in non-program-specific expenses. The cost reduction programs we started last year wrapped up in the second quarter. Non-GAAP R&D declined $8.1 million versus the same period a year ago, which works out to a 14% reduction. Non-GAAP G&A rose $0.3 million, or 2%, over the prior year. In the quarter, we recognized all of the remaining deferred revenue from the Pfizer collaboration agreement. So as we move forward, no revenue recognition will relate to the original Pfizer collaboration. On top of that, we recorded a liability of $52.7 million to cover the estimated remaining liabilities tied to the VEPPANU runout costs; as a result, our future obligations under the collaboration agreement will be booked against the accrual and won't hit our P&L. We're still holding to our cash runway guidance into the second half of 2028. By doing that, we can fund operations through key data milestones in the months ahead and keep supporting our highly differentiated pipeline programs, which could meaningfully improve patients' lives. With that, I'll hand the call over to Randy for closing remarks.

Randy Teel executive
#5

Randy? Appreciate it, Andrew. As we move into the back portion of 2026, we see a number of chances to push forward our goal of creating groundbreaking, transformative treatments for patients. Key catalysts lie ahead in the months to come, and our balance sheet remains strong enough to carry us to crucial milestones. To wrap up, I want to express gratitude to the patients, the investigators, and everyone on the Arvinas team for their ongoing backing and dedication, which help us fulfill our mission.

Jeff Boyle executive
#6

Thanks, Randy. Operator, can you please open the queue?

Nick Lorusso analyst
#7

Regarding 393, could you share more about your thinking on the development path, particularly given the data expected mid next year with the glofi combo? Might that serve as a catalyst for a potentially pivotal trial in an earlier line setting alongside bispecifics? Any perspective would be appreciated. Yes.

Randy Teel executive
#8

Yes is the short answer. The long answer is that within the NHL space, there are numerous opportunities to chase, correct? And as we've discussed over the years, our view is that although many therapies exist across lines of therapy and across the different diseases now — plenty of chemo, plenty of CAR-T, plenty of bispecifics — what remains scarce is orally bioavailable, tolerable small molecules. So our thinking is that a BCL6 degrader might fit into several areas within the disease landscape. At this stage, since we're in the Phase I dose escalation, it's a bit early to say precisely where we intend to go, but we can certainly discuss the options, right? So as early options, later line monotherapy seems sensible — consider fourth-line LBCL, perhaps third-line LBCL, consider later line AITL T cell disease, where we've already been enrolling patients in our Phase I trial. As we progress into combinations, that might unlock further access to the third-line LBCL space, second-line LBCL and possibly advancing in T cell disease too; so there are many different directions we could take. And the common thread, I think, is that reaching any of them requires getting through the monotherapy dose escalation, demonstrating some efficacy, demonstrating some signals there. We need to show we can be combined with other therapies, most immediately a bispecific such as glofi. And after we've accomplished that, I think discussing where we'll go next becomes much easier, especially as the landscape keeps evolving around us.

Jacob Goell analyst
#9

Jacob Goell here, filling in for Derek. Could you give some color on where ARV-102 is headed in PSP? And given the regulatory conversations you've had lately, how should we think about the timing and the registration route?

Randy Teel executive
#10

Sure. Let me quickly recap our starting point this year: we kicked things off with two Phase I studies — one among healthy volunteers, another in PD patients — and our intention across the year was to launch two additional studies, a Phase Ib here in the U.S. plus a globally run study designed to support registration. What we told everyone a couple of months back is that following our IND submission to the FDA, the agency requested that we hold off on kicking that study off; so in technical terms, that amounts to a clinical hold ahead of launching U.S. studies. Then this morning, we shared that given the several regulatory discussions now underway, with back-and-forth continuing, getting those studies started will probably stretch into 2027. Broadly speaking, for the registrational route in PSP, we envision a two-part effort — the Phase Ib plus a registrational study — and that remains our target. If we're talking about a registration-directed pathway in PSP where no patients have been dosed as yet, the study would likely run over a longer stretch. Everything we've run to this point has lasted just 28 days. So in PSP patients, dosing on the order of 6 months or a year is what we'd look to begin with a registrational study. It's certainly worth noting that while we continue going back and forth with the various regulatory authorities — which is actually quite valuable, since we're receiving input from the 3 major agencies all at this moment — we'll use that to lock in the path we'll ultimately embark on, which, as we've stated, is in 2027.

Li Watsek analyst
#11

Perhaps I could ask something else about ARV-393. When you report the Phase I monotherapy cohorts later in the year, what would count as a favorable result? From what you're saying, it seems those doses will fall in the subtherapeutic range. And regarding the combination with glofi, could you tell us where the dose levels stand at this point? Did you also begin at subtherapeutic levels, and what are the early signs on whether the two can be combined?

Randy Teel executive
#12

Yes. For that second question, the brief response is affirmative. To give some background, as we've discussed elsewhere, to our knowledge we were the first company to begin work on BCL6, or at minimum the first to move it into the clinic. Given that, along with certain other considerations, feedback we received led us to begin BCL6 monotherapy at a very low dose; and as we've noted while addressing operational matters, enrollment has definitely been slower than we'd have preferred. Conversely, now that we've moved nearer to the exposures predicted to be efficacious, we have observed a distinct increase. And in the combination trial, which got underway a couple of months ago, enrollment has been quite robust from the very beginning; so regarding the data we'll have by the end of the year, you were correct to point out that for most patients we will still be well within — beneath the efficacious range. At the doses we've reached now, we're beginning to achieve the exposure we'd expect to be efficacious; so we'll begin to see some of that. We also noted that we've been enrolling a larger share of patients with T-cell lymphomas than we'd have expected given the overall population. So we believe it makes sense to concentrate on that population and the upcoming disclosure. And then, as we discussed looking toward next year, concentrating on LBCL patients both as monotherapy and in combination. The data released at the end of this year will definitely center on mono. We don't expect to share combo data; for the combo we didn't begin as low as we did for the mono, but it certainly is starting — it certainly did start at levels that, in monotherapy, weren't predicted to be efficacious among patients with B-cell lymphomas.

Edward Tenthoff analyst
#13

I'm excited to see additional data come out later this year, and congratulations on everything you've accomplished. So my question is about SBMA and 227 — this is a really fascinating mechanism. Can you just verify that the IND has cleared, and what exactly are we holding out for — sorry, the — what stage are you at with multiple ascending dosing? And could you describe — you brought up exposure and degradation. In SBMA, what clinical endpoints would we eventually be modeling or anticipating?

Randy Teel executive
#14

I might hand this over to Angela shortly for some of the forward-looking questions. To restate our position on that, correct? So 027 has been administered to healthy volunteers; the single ascending dose part of the trial is now finished, and the multiple dose part has just started. That's going to keep going. We plan to report some data at the start of, or during the first half of, next year. In the later stages of that Phase I study, we do expect to enroll some patients who have SBMA. And to restate this for everybody, this program — well, SBMA is definitely a rare disease. In major markets, we're talking about 10,000 to 13,000 patients, roughly. What's excellent about this target is that we're going after the true driver of the disease. So the disease is driven by polyglutamine AR. That's the thing we're degrading. It isn't an upstream transcription factor or another factor that we're degrading — we're degrading the actual cause of disease. Regarding the next phases, we've discussed being able to advance into registrational-intent studies even following Phase I; but Angela, I'd like to invite you to say a bit more about the plans there, and the endpoints, and so forth.

Angela Cacace executive
#15

All right. Looking ahead, what we truly want to show is our ability to hit a 50% decrease in the polyglutamine repeat androgen receptor. Across our preclinical work and other preclinical work, that 50% reduction is what we're trying to reach in muscle, so from a biomarker standpoint that's the objective, and we'll be evaluating several additional endpoints too. Those are going to serve as the early endpoints. Showing a functional change won't be possible for us until we get into the registrational studies that Randy brought up. And in those, we'll be examining meaningful scales, for example the SBMA functional rating scale, along with those endpoints too.

Jon Miller analyst
#16

Nice work on the quarter's advances, everyone. First, a follow-up regarding polyQ-AR. You mentioned there will be a few patients next year. Should I be correct in thinking we ought not to anticipate solid translation of degradation rates from healthy volunteers over to patients whose baseline protein levels differ? If so, do certain measures in healthy volunteers seem likely to carry over well to eventual degradation efficiency among patients—and thus to efficacy and functional endpoints? Likewise, for the other data sets where early data will arrive—I have HPK1 in mind, where dosing in healthy volunteers comes first—are there specific endpoints we ought to watch for once that data appears that you believe will translate effectively?

Randy Teel executive
#17

Okay; regarding 027, the brief response about translating 027's degradation in polyglutamine AR, which patients might have, against wild-type AR, which healthy volunteers will have, is that there's no difference. We degrade wild-type AR and polyQ-AR essentially identically; that will prove quite useful to observe, as I noted, when we share healthy volunteer data during the first half of next year—to repeat, a few elements there are new for us, and we're eager to learn whether we can accomplish them. The first is achieving an orally available PROTAC in muscle. That by itself is something we haven't pursued previously. The second is achieving degradation in that tissue. We believe that if degradation of wild-type AR can be observed in healthy volunteers, it will signal strongly that we can degrade the disease-causing polyQ-AR in patients; so I'd say the translatability there should be fairly strong. I can turn to the HPK1 question, but Angela, anything to add regarding the polyQ question?

Angela Cacace executive
#18

And I'd just like to mention as well, John, that we examined skeletal muscle produced from iPSCs taken from healthy volunteers as well as from SBMA patients, and the pharmacology turned out to be completely intact — which is precisely the translation Randy told us we would see. So that is what we're aiming for, and it's the basis for our confidence.

Randy Teel executive
#19

Regarding the HPK1 program, 6723: as mentioned earlier today, dosing of patients is set to begin in the very near future. Our rationale is that this marks our initial IO therapy. Consequently, the first few studies will resemble other oncology studies quite closely, correct? To be clear, these involve patients rather than healthy volunteers; the design is an escalation one; and we'll be examining monotherapy. The Phase I also incorporates a combination arm. We believe it's truly essential there to demonstrate some early signals of efficacy and, naturally, safety, tolerability, and the ability to combine as well. The HPK1 program is fascinating, isn't it? As our first IO therapy, it presents a fairly substantial opportunity; we're well aware we must show something that HPK1 inhibitors haven't demonstrated — namely, strong response rates and so forth among patients — yet we're highly confident we can achieve that, drawing on our preclinical data, which strongly supports it, including some recent preclinical findings this year showing we can produce differential effects in generating responses, achieving inhibition, and impacting the tumor microenvironment in ways HPK1 inhibitors couldn't, PD-1 therapies couldn't. Thus, we hold solid confidence as we enter Phase I, and we look forward to sharing those results.

Yigal Nochomovitz analyst
#20

Two things for me, the first about BCL6. Randy, I believe you said enrollment has been somewhat sluggish at the subtherapeutic doses, yet you also noted that at the lower doses you observed some effective responses. So I was simply attempting to reconcile those 2 points. My assumption would have been that if responses appeared below therapeutic doses, that ought to accelerate the enrollment curve. Then second, regarding LRRK2, could you comment on the fact that — clearly, since the prior earnings, Biogen and Denali ran the Phase IIb for their inhibitor, which, as you're aware, failed, but I would really like to hear your perspective on that and on why the degrader might represent a more promising path?

Randy Teel executive
#21

Yes; so regarding BCL6, your statement is accurate, and you did highlight a bit of a contradiction, one we're definitely aware of; so yes, we began quite far beneath the predicted efficacious range. And the additional feedback we received concerned the design and its escalation. So not only do we begin low — pardon me, not only do we begin low, we've also escalated rather slowly. Observing the responses we have has definitely been helpful; but I believe particularly where we're running the trial in the U.S., particularly among LBCL patients, there are a fair number of other options available to patients before they enter a clinical trial. And I believe there's considerable natural reluctance among physicians to place patients on a dose they might not anticipate being efficacious when other options exist. So I do acknowledge that it has definitely picked up as we've gotten nearer. The responses have been helpful; and it's yet another reason we're eager to get some of this data out by the end of the year and particularly regarding T cell patients, where we believe we'll be the first to share data for a BCL6 degrader examining that patient population. Regarding the LRRK2 program in LUMA, I think that — and Angela, please try to jump in here too. As we've been asked about that over the past couple of months, the questions have mostly taken the same course, which is, look, the LUMA Trial didn't work; we didn't expect it to work. Is there anything to learn? And I think for us, what we've really concentrated on since this program's start was truly the fact that we don't believe inhibiting the kinase function of LRRK2 is sufficient. We believe there are other aspects of LRRK2. There's GTPase function, there's scaff function that we know drive activity, inflammation and the lysosomal capabilities by the cells. So we regard those as essential. Consequently, when a program reportedly achieves roughly 30% kinase inhibition, seeing it fail wasn't a huge shock to us. That doesn't hold us back from what we're pursuing. With a LRRK2 degrader, our belief is that it can address all 3 distinct factors and features of LRRK2, and we believe that's significant. We also believe that breaking it down will plainly influence the kinase function to an even greater degree. Nor does it divert us from our path, which, as we've discussed, begins in PSP, where unmet need is genuinely substantial in a neurodegenerative disorder that progresses very rapidly compared with PD in any case, and then eventually PD too.

Angela Cacace executive
#22

To quickly jump in on that, Yigal: from a biology standpoint, we get why these inhibitors aren't failing to work, correct? In the brain, we observed target engagement boosted more than 50-fold, along with engagement of the phosphoRab pathway. And after that, at MDS we'll discuss some synaptic markers that are exciting and that, in our view, will genuinely demonstrate the degrader behaves differently in Parkinson's disease patients, through examining eye tracking plus CSF synaptic markers showing changes unlike anything seen before in markers that predict progression in Parkinson's disease.

Etzer Darout analyst
#23

A pair of things, actually — one regarding the pipeline, and possibly another directed at Andrew. To start with the pipeline: should we anticipate that tumor types will be enrolled in the HPK1 degrader program in a manner comparable to what has been observed with HPK1 inhibitors, such as gastric and lung? Any information on that front would be useful. Also, is PD-1 the most probable first combination partner at the outset? Then, for Andrew, perhaps you could assist us with how we ought to approach thinking about the modeling of licensing costs going forward? Anything you can offer there would be valuable too.

Randy Teel executive
#24

Okay. Sure. So regarding — perhaps I'll take the simplest ones to begin with. PD-1, yes, that is the probable first combination partner. I haven't specified exactly which one, but we will definitely get into that as months pass. Tumor types, not far off either. Something like lung is the correct area to be considering. That trial will enroll patients who have received prior immunotherapy. And consider it a traditional sort of escalation trial from which we'll get into data. I haven't discussed when, but as that gets going, it becomes easier to talk about data coming. Andrew, questions on modeling?

Andrew Saik executive
#25

Certainly, absolutely. So at a broad level, there are indeed numerous modifications to how we handle the accounting, and if this doesn't resolve what you're asking about, I'm glad to address a follow-up. Broadly speaking, throughout the duration of the initial Pfizer collaboration agreement, we had been deferring revenue from it. Because of the out-license to Rigel, we concluded that everything we were contributing to that collaboration has been finished. As a result, we pushed all remaining collaboration revenue through the P&L. Consequently, moving forward, there will be no further revenue recognition. We still carry tail liabilities associated with closeout expenses for the VEPPANU development plan. A liability for that was recorded on the balance sheet. Once the Q is released, you will observe a current portion amounting to $28.4 million, alongside a long-term portion of $24.3 million, which adds up to $52.7 million. Thus, any future payments we make tied to that collaboration cost will be applied toward reducing that liability; so in essence, our P&L moving ahead is more or less purified of the earlier VEPPANU collaboration agreement; milestones and royalties will be recorded going forward, though these will be somewhat conventional, and they'll consist of genuine royalties received from Rigel in future periods. Beyond that, we also introduced that cost of sales line. The purpose was simply to separate Yale payments out from our regular G&A; so that cost of sales line will appear; at present, it consists entirely of payments to Yale; we owe Yale a modest royalty on whatever royalties come in, and they also receive a small share of milestones moving forward. So you'll find those captured within that collaboration — cost of revenue line. Kindly tell me whether that responded to what you asked. I realize that's quite a bit.

Paul Choi analyst
#26

First off, I'd like to ask about LRRK2. You mentioned that more biomarker data will be shared in October. Could you give us a sense of what the cadence across 2027 might look like regarding further updates for that program, along with any extra clinical measures or possible steps forward to the next stage? My second question concerns BCL6. Once you share the glofi combination data in mid-2027, thinking about clinical development, could you lay out how you're approaching possible comparator arms relative to the monotherapy trial, and how you're considering that going forward?

Randy Teel executive
#27

All right. Yes. Regarding LRRK2, let me restate my earlier comments about where things stand with 102, which is truly centered on the regulatory path, correct? What we're concentrating on at this moment is taking in feedback and building out that strategy for how we proceed with the studies we've previously discussed, all while folding in that feedback. So regarding the timing of trials, essentially the sequence would be that we'd want to get started; that's how it stands. As for offering a little more clarity on our direction, once we launch those trials, when we get near or perhaps even sooner, we'll definitely discuss how they're coming together; however, the rhythm after the biomarker data we intend to present at MDS will truly depend on those trial initiations. Now for BCL6, look, as we progress, like I said, every path runs through the monotherapy and the combination currently with glofi, and we'll say a bit more about where we head afterward. There are many possibilities, right? The bispecifics, there's more than one; those represent potential combinations. There's chemo, there are other options too. I believe we'll genuinely need to observe how the landscape shifts to get a sense of where the puck is headed, to determine where combining makes the most sense for us. Let me restate my point about the chance to go earlier and faster using monotherapy approaches, and then the capacity to follow up with combination approaches that could reach larger patient populations in earlier lines of therapy; past that, it's somewhat difficult to pin down what the specifics will be. But since we began discussing this program, as we've shared our progress, certainly, many companies are keen on this space, including strategic ones that are evidently pursuing the conventional route in the NHL space, which means finding ways to expand the treatment combinations we can deliver to patients to prolong responses and bring responses to more patients.

Blake Gitler analyst
#28

This is Blake, filling in for Jit. One brief thing about ARV-102. Is there still a specific PSP group you plan to go after? Or will this be a study open to everyone, with more of a focus on Richardson syndrome cases or particular LRRK2 variants?

Randy Teel executive
#29

Perhaps Angela can add a bit more detail on this. The briefest way to put it is that you aren't — your thinking is on the right track here, correct, meaning we could examine the full PSP population. Richardson represents the biggest subtype. As for getting more specific than that, my sense is that's unlikely; but Angela, maybe you can elaborate a little on our approach to that population.

Angela Cacace executive
#30

Okay. My view is that we wouldn't put any additional limits in place. The population with Richardson syndrome progresses quite uniformly, and that's exactly what draws us to it; we also appreciate having that specific focus, yet nothing here stops us from broadening out to encompass all PSP. I hope that answers your question.

Randy Teel executive
#31

Appreciate it, operator, and thank you all for being here this morning. We're eager to share more updates down the road, and once again, thank you.

Operator operator
#32

This concludes today's conference call. Thank you for your participation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Arvinas, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Arvinas, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.